https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19331
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADSofosbuvir / Velpatasvir / Voxilaprevir can inhibit OATP1B1 and increase the plasma concentration of Voxilaprevir Atorvastatin.
–
–
–
Possible increase of adverse effects.
Increased risk of myopathy and rhabdomyolysis.
Use this combination with caution.
We do not recommend more than 10 mg per day.
Monitor closely for adverse effects.
–
Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.
CK
Lipidic profile
–
–